Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUL-042 for COVID-19 Prevention in Exposed Adults
NCT04313023Phase 2Completed
- Sponsor
- Pulmotect
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing PUL-042 with Placebo (2 arms). Primary endpoint: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI at 28 days. Started Jun 2020; status: completed.
02
Drugs
PUL-042
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04313023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313023.